Skip Navigation


European Heart Journal Advance Access originally published online on June 11, 2008
European Heart Journal 2008 29(16):1975-1982; doi:10.1093/eurheartj/ehn253
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/16/1975    most recent
ehn253v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mehilli, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehilli, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis

Julinda Mehilli, Robert A. Byrne, Anna Wieczorek, Raisuke Iijima, Stefanie Schulz, Olga Bruskina, Jürgen Pache, Rainer Wessely, Albert Schömig, Adnan Kastrati* for the Intracoronary Stenting and Angiographic Restenosis Investigators – Test Efficacy of Rapamycin-eluting Stents with Different Polymer Coating Strategies (ISAR-TEST-3)

Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Technische Universität, Lazarettstrasse 36, 80636 Munich, Germany

Received 13 December 2007; revised 15 May 2008; accepted 23 May 2008; online publish-ahead-of-print 11 June 2008.

* Corresponding author. Tel: +49 89 1218 4577, Fax: +49 89 1218 4053, Email: kastrati{at}dhm.mhn.de

See page 1930 for the editorial comment on this article (doi:10.1093/eurheartj/ehn304)

Aims: The objective of this study was to assess the non-inferiority, in terms of anti-restenotic efficacy, of both biodegradable-polymer (BP) and polymer-free (PF) stents compared with permanent-polymer rapamycin-eluting (PP; Cypher) stent.

Methods and results: Patients with de novo coronary lesions in native vessels were randomly assigned to receive a BP stent, a PF stent or a PP stent. The primary endpoint was in-stent late lumen loss at follow-up angiogram.

A total of 605 patients were enrolled: 202 patients received BP stents, 202 were treated with PP stents, and 201 received PF stents. Repeat angiography was available for 492 patients (81.3%). Mean late lumen loss at 6–8-month angiographic follow-up was 0.17 ± 0.45 mm in the BP stent group, 0.23 ± 0.46 mm in the PP cohort, and 0.47 ± 0.56 mm in the PF stent group. The BP stent met pre-specified criteria for non-inferiority (P < 0.001), whereas the PF stent did not (P = 0.94). There were no differences in safety outcomes.

Conclusion: Both BP and PF stents have a 1-year safety profile similar to that of the PP stent. Whereas the PF stent provided an inferior efficacy, the BP stent is at least as effective as the PP stent in terms of anti-restenotic efficacy.

Key Words: Biodegradable • Coronary restenosis • Drug-eluting stents • Polymer • Rapamycin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Biodegradable coating for drug-eluting stents—more than a facelift?
Kari O. Niemelä
EHJ 2008 29: 1930-1931. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
J. R. Costa Jr, A. Abizaid, R. Costa, F. Feres, L. F. Tanajura, A. Abizaid, G. Maldonado, R. Staico, D. Siqueira, A. G.M.R. Sousa, et al.
1-Year Results of the Hydroxyapatite Polymer-Free Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions: The VESTASYNC I Trial
J. Am. Coll. Cardiol. Intv., May 1, 2009; 2(5): 422 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
R. A. Byrne, J. Mehilli, R. Iijima, S. Schulz, J. Pache, M. Seyfarth, A. Schomig, A. Kastrati, and for the Intracoronary Stenting and Angiographic Re
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents
Eur. Heart J., April 2, 2009; 30(8): 923 - 931.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
R. A. Byrne, R. Iijima, J. Mehilli, S. Pinieck, O. Bruskina, A. Schomig, and A. Kastrati
Durability of Antirestenotic Efficacy in Drug-Eluting Stents With and Without Permanent Polymer
J. Am. Coll. Cardiol. Intv., April 1, 2009; 2(4): 291 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
K. O. Niemela
Biodegradable coating for drug-eluting stents--more than a facelift?
Eur. Heart J., August 2, 2008; 29(16): 1930 - 1931.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.